• Circassia pulls plug on AZ agreement pharmatimes
    April 10, 2020
    Circassia Pharmaceuticals is pulling back from its development and commercialisation agreement with AstraZeneca for US commercial rights to COPD therapies Tudorza (aclidinium) and Duaklir (aclidinium/formoterol).
PharmaSources Customer Service